MX369114B - Proceso para la preparación de nanopartículas de polisacáridos. - Google Patents

Proceso para la preparación de nanopartículas de polisacáridos.

Info

Publication number
MX369114B
MX369114B MX2014010979A MX2014010979A MX369114B MX 369114 B MX369114 B MX 369114B MX 2014010979 A MX2014010979 A MX 2014010979A MX 2014010979 A MX2014010979 A MX 2014010979A MX 369114 B MX369114 B MX 369114B
Authority
MX
Mexico
Prior art keywords
group
amino
aldehyde groups
aliphatic
aldehyde
Prior art date
Application number
MX2014010979A
Other languages
English (en)
Other versions
MX2014010979A (es
Inventor
Iga Wasiak
Tomasz Ciach
Original Assignee
Nanovelos Sp Zo O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanovelos Sp Zo O filed Critical Nanovelos Sp Zo O
Publication of MX2014010979A publication Critical patent/MX2014010979A/es
Publication of MX369114B publication Critical patent/MX369114B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B1/00—Preparatory treatment of cellulose for making derivatives thereof, e.g. pre-treatment, pre-soaking, activation
    • C08B1/08—Alkali cellulose
    • C08B1/10—Apparatus for the preparation of alkali cellulose
    • C08B1/12—Steeping devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
    • C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un proceso para preparar nanopartículas a partir de polisacáridos en una suspensión acuosa, el método caracterizado porque comprende los pasos de: A).- Proveer un polisacárido o derivado del mismo; B).- Oxidar dicho polisacárido o derivado del mismo para obtener un polisacárido o derivado del mismo oxídado que comprende grupos aldehído, en donde la oxidación se lleva cabo hasta obtener un grado de oxidación de 0.1% a 80% de los anillos de azúcar en el polisacárido; C).- Combinar el polisacárido o derivado del mismo oxidado con al menos una sustancia activa que comprende un grupo amina primario o secundario en agua y un solvente orgánico de tal forma que la relación molar de grupos aldehídos del polisacárido o derivado del mismo oxidado a grupos amina de la sustancia activa es mayor a 1, y permitir que los grupos amina reaccionen con los grupos aldehídos para proveer un polisacárido o derivado del mismo oxidado a grupos amina de la sustancia activa es mayor a 1, y permitir que los grupos amina reacciones con los grupos aldehídos para proveer un polisacárido o derivado del mismo modificado, son formar nanopartículas; D).- Combinar el polisacárido o derivado del mismo modificado con al menos un agente formador de nanopartículas que comprende un grupo amina primario o secundario en agua o una mezcla de agua y un solvente orgánico, y permitir que los grupos amina reaccionen con los grupos aldehídos, de tal forma que la reacción de los grupos amina con los grupos aldehídos produce nanopartículas de polisacáridos en una suspensión acuosa; en donde dichas nanopartículas de polisacárido comprende el polisacárido o derivado del mismo oxidado, el al menos una sustancia activa, y el al menos un agente formador de nanopartículas; en donde el al menos un agente formador de nanopartículas se selecciona del grupo qe consiste de: butilamina, pentilamina, hexilamina, octiloamina, decilamina, dodecilamina, tetradecilamina, hexadecilamina, ciclohexilamina, bencilamina, etilfenilamina, esfingosinas, amida del ácido oleico, amida de ácido palmítico, hidrazida del ácido esteárico, hidrazida del ácido palmítco, hidrazida de ácido oleico, leucina, isoleucina, valina metionina, alamina, fenilalanina , cefalina y sales de amina de las mismas; en dodne la sustancia activa se seleccional del grupo que consiste de: danunorubicina, doxorubicina, aminoacridinas, cisplatino, metotrexato, citarabina, gemcitabina, dapsona, Aciclovir, azidotimidina, 5-fluorouracilo, mercaptropurina, imatinib, sunitinib, bleomicina, actinomicina, mitamicina, dactinomicina, melfalán, temozolomida, celocoxib, nelarabina, cladribina, isoniazida, 9-aminoacridina, 4´,6-diamidino-2-fenilind ol, rodamina, rojo neutro, azul de tripano y sales de los mismos; en donde el polisacárido se selecciona del grupo que consiste de: dextrano, almidón, derivados de almidón hidroxietilalmidón, amilosa derivados de amilosa, derivados de celulosa, hidroxietilcelulosa, hidroxipropilcelulosa, carboximetilcelulosa, glucógeno, ácido hialurónico, heparina, ácido algínico, carragenina y sales de los mismos; en donde no hay nanopartículas presente en el proceso hasta que la reacción del paso D produce las nanopartículas del polisacárido; en donde las únicas nanoparticulas en suspensión acuosa son las nanopartículas de polisacárido creadas en el paso D, y en donde las reacciones de los pasos C y D son conducidas independientemente a un pH de la solución de 1 a 9 y a una temperatura de 10 a 100°C. .
MX2014010979A 2012-03-14 2013-03-12 Proceso para la preparación de nanopartículas de polisacáridos. MX369114B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL398450A PL221351B1 (pl) 2012-03-14 2012-03-14 Sposób otrzymywania nanocząstek polisacharydowych
PCT/PL2013/000030 WO2013137755A1 (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles

Publications (2)

Publication Number Publication Date
MX2014010979A MX2014010979A (es) 2015-02-24
MX369114B true MX369114B (es) 2019-10-29

Family

ID=48014274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010979A MX369114B (es) 2012-03-14 2013-03-12 Proceso para la preparación de nanopartículas de polisacáridos.

Country Status (14)

Country Link
US (1) US10258579B2 (es)
EP (1) EP2825563B1 (es)
JP (1) JP6470169B2 (es)
CN (1) CN104169305B (es)
AU (1) AU2013232850B2 (es)
BR (1) BR112014022767B1 (es)
CA (1) CA2866682C (es)
ES (1) ES2780387T3 (es)
IL (1) IL234572A (es)
IN (1) IN2014MN01651A (es)
MX (1) MX369114B (es)
PL (1) PL221351B1 (es)
RU (1) RU2632019C2 (es)
WO (1) WO2013137755A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6640736B2 (ja) * 2014-12-12 2020-02-05 日本化薬株式会社 核酸代謝拮抗剤が結合した多分岐化合物
WO2018026777A1 (en) * 2016-08-01 2018-02-08 Hppe, Llc Biopolymers for fugitive dust control
US10736964B2 (en) * 2017-05-01 2020-08-11 China Medical University Immunomagnetic nanocapsule and kit for treating cancer
CN107446054B (zh) * 2017-08-11 2021-05-18 武汉理工大学 一种生物质基纳米粒子及其制备方法和应用
PL424773A1 (pl) * 2018-03-06 2019-09-09 Nanovelos Spółka Akcyjna Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów
CN108676181B (zh) * 2018-05-30 2022-05-17 江西师范大学 通过二醛基纤维素制备纤维素纳米颗粒的方法
CN108553448A (zh) * 2018-05-30 2018-09-21 江西师范大学 一种pH响应的药物缓释纤维素纳米颗粒的制备方法
PL240772B1 (pl) 2018-06-11 2022-06-06 Nanothea Spolka Akcyjna Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii
CN112353781B (zh) * 2020-11-12 2022-08-19 云南开放大学 一种药物载体空心纳米球的制备方法
CN112516310B (zh) * 2020-12-11 2022-11-29 武汉理工大学 一种肿瘤酸环境响应的纳米前药的制备方法及其应用
CN112830979A (zh) * 2021-01-15 2021-05-25 江南大学 一种改性黄原胶及其制备方法与应用
CN113800501B (zh) * 2021-10-08 2023-04-18 山西大学 一种用于检测pH和精氨酸的橙红色荧光碳点的制备方法及其应用
WO2023092208A1 (pt) * 2021-11-25 2023-06-01 Universidade Estadual De Campinas Processo de obtenção de solução polimérica injetável fotoreticulável, solução polimérica injetável fotoreticulável e seus usos
CN115463262B (zh) * 2022-08-11 2024-06-04 南方医科大学第五附属医院 一种水凝胶复合修复补片及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU825542A1 (ru) * 1979-04-04 1981-04-30 Inst Orch Chimii Aka Способ получения n-производных полисахаридов 1
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4693912A (en) * 1985-02-28 1987-09-15 Technicon Instruments Corporation Lyophilization of reagent-coated particles
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
JPS62221637A (ja) * 1986-03-24 1987-09-29 Green Cross Corp:The 制癌剤−抗体複合体の製造方法
JPS62283101A (ja) * 1986-05-30 1987-12-09 Green Cross Corp:The 制癌作用物質複合体の製造方法
JPS63264427A (ja) * 1986-12-17 1988-11-01 Green Cross Corp:The 制癌作用物質複合体
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
EP0999222A1 (en) 1998-11-02 2000-05-10 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Carbohydrate oxidation products
RU2233654C2 (ru) * 1998-11-20 2004-08-10 Ртп Фарма Инк. Диспергируемые стабилизированные фосфолипидом микрочастицы
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
MXPA02012791A (es) 2000-06-29 2003-12-11 Daiichi Seiyaku Co Compuestos dds y metodo para prepararlo.
DE10129369C1 (de) * 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
EP1531868A2 (en) * 2002-06-03 2005-05-25 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
KR100578382B1 (ko) * 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
KR101465994B1 (ko) * 2005-05-27 2014-11-27 로이어 바이오메디칼 인코포레이티드 생체재흡수성 중합체 매트릭스 및 이의 제조방법과 사용방법
EP1937304A2 (en) 2005-08-24 2008-07-02 Novartis Vaccines and Diagnostics S.r.l. Zwitterionization of capsular saccharides
CN101273066B (zh) * 2005-09-09 2013-10-16 郑特来 用于递送抗癌剂的水溶性壳聚糖纳米颗粒及其制备方法
EP1926498A2 (en) * 2005-09-22 2008-06-04 Hadasit Medical Research Services And Development Company Ltd. Dextran and arabinogalactan conjugates of therapeutically active compounds
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
US8545871B2 (en) * 2008-11-19 2013-10-01 Actamax Surgical Materials Llc Fibrous tissue sealant and method of using same
CZ302503B6 (cs) * 2009-12-11 2011-06-22 Contipro C A.S. Zpusob prípravy derivátu kyseliny hyaluronové oxidovaného v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd a zpusob jeho modifikace
US20130178437A1 (en) * 2010-07-09 2013-07-11 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Also Published As

Publication number Publication date
CN104169305A (zh) 2014-11-26
CA2866682C (en) 2016-05-17
ES2780387T3 (es) 2020-08-25
BR112014022767A2 (es) 2017-10-03
RU2014133962A (ru) 2016-03-20
RU2632019C2 (ru) 2017-10-02
PL221351B1 (pl) 2016-03-31
AU2013232850A1 (en) 2014-09-11
WO2013137755A1 (en) 2013-09-19
EP2825563A1 (en) 2015-01-21
US10258579B2 (en) 2019-04-16
IL234572A (en) 2017-01-31
BR112014022767B1 (pt) 2021-08-31
JP2015514059A (ja) 2015-05-18
CA2866682A1 (en) 2013-09-19
MX2014010979A (es) 2015-02-24
PL398450A1 (pl) 2013-09-16
EP2825563B1 (en) 2020-02-05
CN104169305B (zh) 2016-07-27
US20150072946A1 (en) 2015-03-12
AU2013232850B2 (en) 2016-01-07
JP6470169B2 (ja) 2019-02-13
IN2014MN01651A (es) 2015-05-29

Similar Documents

Publication Publication Date Title
MX369114B (es) Proceso para la preparación de nanopartículas de polisacáridos.
PL412787A1 (pl) Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
MX346052B (es) Procedimiento para la sintesis de acido 2,5-furandicarboxilico.
WO2009128973A3 (en) Methods for the production of silver nanowires
TR201904615T4 (tr) 1,4-bütandiol üretme prosesi.
SE1651252A1 (sv) Method of producing a sodium iron(II)-hexacyanoferrate(II) material
MX2019011095A (es) Composicion adhesiva y metodo para preparar la misma.
MX348807B (es) Composiciones activables para la liberacion controlada en dos etapas de sustancias quimicas activas.
WO2012158861A3 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
MX2018000196A (es) Procedimiento para la preparacion de un derivado de furfural.
BR112015009055A2 (pt) método para purificar 1,4-diaminobutano, 1,4-diaminobutano, e poliamida
AR106195A1 (es) Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis
EP2733134A3 (en) Alternative to tetrazene
UA104857C2 (uk) Спосіб одержання діоксиду урану у формі зерен сферичної й неправильної форми
FR2973370B1 (fr) Procede a faible cout pour la preparation d'un acide o-acetylsalicyclique et d'un acide amine basique
BR112018069201A2 (pt) composição enzimática e método para a preparação de uma composição enzimática em forma líquida
RS53485B (en) PROCEDURE FOR OBTAINING MULTIFUNCTIONAL MICRO AND NANOCOMPOSITE SPHERE WITH SILVER NANOPARTICLES COATED WITH BIODEGRADABLE POLYMERS
RU2008138808A (ru) Способ получения органофильного бентонита
RU2458930C1 (ru) Способ получения гуминосодержащего хелата железа
PL410425A1 (pl) Nowe alkoksymetylodi(2-hydroksyetylo)metyloamoniowe ciecze jonowe z słodkim anionem oraz sposób ich wytwarzania
Liu Cyclic voltametric Studies on the interaction of adrenaline with formic acid and acetic acid
TH133922B (th) องค์ประกอบเวสซิเคิล (vesicle composition)
RU2009114018A (ru) Способ лонгирования распада карбамида из комплекса в рубце жвачных животных
UA112258U (xx) Спосіб одержання модифікованого крохмалю
UA39632U (uk) Електрохімічний спосіб одержання порошку кобальту

Legal Events

Date Code Title Description
FG Grant or registration